Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini <i>et al</i>.

Ramiro, Sofia; Mostard, Rémy; Landewé, Robert Bm

Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al.

Ramiro, Sofia; Mostard, Rémy; Landewé, Robert Bm.

Ramiro S; Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands sofiaramiro@gmail.com.
Mostard R; Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Landewé RB; Department of Pulmonology, Zuyderland Medical Center, Heerlen, The Netherlands.

Ann Rheum Dis ; 81(10): e203, 2022 10.

Article in English | MEDLINE | ID: covidwho-725378

Subject(s)

COVID-19 Drug Treatment; Methylprednisolone; Antibodies, Monoclonal, Humanized/therapeutic use; Humans; Methylprednisolone/adverse effects; Methylprednisolone/therapeutic use

Keywords

biological therapy; epidemiology; glucocorticoids

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Methylprednisolone / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2022 Document Type: Article Affiliation country: Annrheumdis-2020-218788

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google